Ultime notizie per MediWound (NASDAQ:MDWD) Azioni

MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

MediWound Ltd

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $25 price target.

News

Price Target

Reiteration

Analyst Ratings

MDWD

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $25 Price Target

Guidance

Health Care

General

MediWound Expects 2025 Sales Of $25M Versus Consensus Of $24.98M

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.59) by 38.98 percent. This is a 89.47 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $5.84 million which beat the analyst consensus estimate of $5.75 million by 1.60 percent. This is a 9.40 percent increase over sales of $5.34 million the same period last year.

Earnings

MediWound Q4 2024 GAAP EPS $(0.36) Beats $(0.59) Estimate, Sales $5.84M Beat $5.75M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Corporacion America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAAP#NYSE">CAAP</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $373.00 million. 
• Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) is likely to report quarterly earnings at $1.19 per share on revenue of $674.52 million. 
• Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $294.60 million. 
• GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $430.70 million. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is estimated to report quarterly loss at $0.61 per share on revenue of $5.75 million. 
• Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is expected to report quarterly earnings at $6.25 per share on revenue of $2.33 billion. 
• J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $142.33 million. 
• Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million. 
• Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is projected to report quarterly loss at $0.11 per share on revenue of $269.59 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is estimated to report earnings for its fourth quarter. 
• Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $747.94 million. 
• Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) is projected to report quarterly earnings at $2.93 per share on revenue of $2.35 billion. 
• General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $4.96 billion. 
• One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $15.00 million. 
• Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#NYSE">CWEB</a>) is estimated to report earnings for its fourth quarter. 
• HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) is expected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) is projected to report quarterly earnings at $3.38 per share on revenue of $1.38 billion. 
• Epsilon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSN#NASDAQ">EPSN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $7.22 million. 
• Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) is likely to report earnings for its fourth quarter. 
• TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $47.78 million. 
• Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $1.30 million. 
• SWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKH#NASDAQ">SWKH</a>) is expected to report quarterly earnings at $1.01 per share on revenue of $9.70 million. 
• scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) is projected to report quarterly loss at $0.39 per share on revenue of $12.18 million. 
• CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is likely to report earnings for its fourth quarter. 
• Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $8.89 million. 
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $559.67 million. 
• Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) is estimated to report quarterly loss at $0.41 per share on revenue of $3.88 million. 
• icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.50 million. 
• Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $9.87 million. 
• Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is projected to report quarterly loss at $0.24 per share on revenue of $15 thousand. 
• LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) is estimated to report earnings for its fourth quarter. 
• North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) is estimated to report quarterly earnings at $1.17 per share on revenue of $318.60 million. 
• Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) is likely to report quarterly loss at $0.58 per share on revenue of $2.47 million. 
• Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $732.00 million. 
• Prudential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUK#NYSE">PUK</a>) is expected to report earnings for its Fiscal Year 2024. 
• Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $4.94 million. 
• FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) is expected to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

CAAP

CAPR

CWEB

EPSN

FIVE

GROY

ICAD

JILL

LENZ

LQDA

OLLI

PGEN

PRSO

SCPH

SERA

SRAD

SWKH

TISI

TWFG

Earnings Scheduled For March 19, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>William Blair analyst Andy Hsieh initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Perform rating. Altimmune shares closed at $6.42 on Thursday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Chase Knickerbocker initiated coverage on MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy rating and announced a price target of $39. MediWound shares closed at $16.23 on Thursday. <a href="https://www.benzinga.com/quote/mdwd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Faiza Alwy initiated coverage on CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Buy rating and announced a price target of $89. CoStar Group shares closed at $74.36 on Thursday. <a href="https://www.benzinga.com/quote/csgp/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy rating and announced a price target of $42. Summit Therapeutics shares closed at $18.49 on Thursday. <a href="https://www.benzinga.com/quote/smmt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Yasmeen Rahimi initiated coverage on Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) with an Overweight rating and announced a price target of $48. Avalo Therapeutics shares closed at $6.60 on Thursday. <a href="https://www.benzinga.com/quote/avtx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>

Initiation

Markets

Trading Ideas

AVTX

CSGP

SMMT

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Craig-Hallum analyst Chase Knickerbocker initiates coverage on MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy rating and announces Price Target of $39.

Craig-Hallum Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $39

MediWound Initiates VALUE Global Phase III Trial Of EscharEx In Treatment Of Venous Leg Ulcers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital raised the price target for Autodesk, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $287 to $308. BMO Capital analyst Daniel Jester maintained a Market Perform rating. Autodesk shares closed at $317.96 on Tuesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) from $25 to $18. Baird analyst Mark Altschwager downgraded the stock from Outperform to Neutral. Kohl&#8217;s shares closed at $15.22 on Tuesday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) price target from $15 to $17. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Iris Energy shares settled at $9.56 on Tuesday. <a href="https://www.benzinga.com/quote/IEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group boosted The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $62 to $85. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Kroger shares closed at $60.57 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised New Jersey Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) price target from $46 to $49. Guggenheim analyst Shahriar Pourreza maintained a Neutral rating. New Jersey Resources shares closed at $50.71 on Tuesday.  <a href="https://www.benzinga.com/quote/NJR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets boosted MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) price target from $80 to $100. Northland Capital Markets analyst Mike Grondahl maintained an Outperform rating on the stock. MoneyLion shares closed at $86.64 on Tuesday. See how other analysts view this stock.</li>
<li>Benchmark cut the price target for H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) from $53 to $48. Benchmark analyst Fawne Jiang maintained a Buy rating. H World shares settled at $33.10 on Tuesday. <a href="https://www.benzinga.com/quote/HTHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup boosted Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) price target from $42 to $59. Citigroup analyst Paul Lejuez upgraded the stock from Neutral to Buy. Urban Outfitters shares closed at $40.14 on Tuesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut the price target for MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) from $28 to $25. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. MediWound shares closed at $16.90 on Tuesday. <a href="https://www.benzinga.com/quote/MDWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) price target from $80 to $90. Needham analyst Mike Cikos maintained a Buy rating. Nutanix shares closed at $72.35 on Tuesday. <a href="https://www.benzinga.com/quote/NTNX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42210452/top-3-consumer-stocks-that-are-set-to-fly-in-q4">Top 3 Consumer Stocks That Are Set To Fly In Q4</a></li>
</ul>

Pre-Market Outlook

ADSK

HTHT

IREN

NTNX

URBN

Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and lowers the price target from $28 to $25.

HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $25

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.45) by 117.78 percent. The company reported quarterly sales of $4.36 million which missed the analyst consensus estimate of $6.01 million by 27.49 percent. This is a 8.81 percent decrease over sales of $4.78 million the same period last year.

MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is projected to report quarterly loss at $0.08 per share on revenue of $708 thousand. 
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $164.00 million. 
• Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is expected to report quarterly loss at $0.29 per share on revenue of $194.49 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $9.63 billion. 
• Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $3.71 billion. 
• JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) is estimated to report quarterly earnings at $2.51 per share on revenue of $2.26 billion. 
• Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is expected to report quarterly earnings at $2.69 per share on revenue of $3.03 billion. 
• Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is projected to report quarterly earnings at $1.64 per share on revenue of $2.41 billion. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $675.30 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $276.88 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $26.70 million. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is estimated to report earnings for its third quarter. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.72 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $2.56 billion. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is estimated to report quarterly earnings at $0.69 per share on revenue of $933.86 million. 
• Cadeler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDLR#NYSE">CDLR</a>) is likely to report earnings for its third quarter. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $1.18 billion. 
• American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is projected to report quarterly earnings at $2.37 per share on revenue of $458.29 million. 
• Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is projected to report earnings for its third quarter. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is projected to report quarterly loss at $0.44 per share on revenue of $6.01 million. 
<h3>Companies Reporting After The Bell</h3>
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $562.00 million. 
• Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $54.75 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is expected to report quarterly loss at $0.09 per share on revenue of $113.65 million. 
• Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $747.44 million. 
• Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) is projected to report quarterly loss at $0.21 per share on revenue of $30.59 million. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $1.34 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $3.35 billion. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $983.03 million. 
• Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) is estimated to report quarterly earnings at $2.06 per share on revenue of $24.72 billion. 
• Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $572.16 million. 
• Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is expected to report quarterly loss at $0.92 per share on revenue of $58.91 million. 
• Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is likely to report quarterly earnings at $2.12 per share on revenue of $1.56 billion. 
• Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) is projected to report quarterly earnings at $1.76 per share on revenue of $2.13 billion. 
• Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $79.03 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is likely to report earnings for its third quarter. 
• Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its third quarter. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $116.39 million. 
• HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is expected to report quarterly earnings at $0.93 per share on revenue of $14.00 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBA

AMWD

ARWR

BURL

CDLR

CRWD

DELL

EMBC

ICCM

MANU

NOAH

PNST

TITN

WDAY

Earnings Scheduled For November 26, 2024

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MediWound to report an earnings per share (EPS) of $-0.44.
The announcement from MediWound is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.24 in the last quarter, leading to a 4.01% increase in the share price on the following day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.41</td>
<td>-0.23</td>
<td>-0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-0.39</td>
<td>-0.19</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550447_0.png" alt="eps graph" />
<h3>Performance of MediWound Shares</h3>
Shares of MediWound were trading at $16.48 as of November 22. Over the last 52-week period, shares are up 96.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: MediWound

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $28 price target.

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target

EscharEx against collagenase ointment (marketed as SANTYL in the U.S. and IRUXOL in Europe)&nbsp;

Mediwound Will Initiate A Controlled, Multicenter Phase 2 Study For EscharEx Against Collagenase Ointment For Venous Leg Ulcers. Scheduled To Commence In 2025, This Phase 2 Study Will Run Concurrently With The Company's Phase 3 Trial

Biotech

MediWound NexoBrid For Treatment Pediatric Patients With Severe Thermal Burns Approved By FDA

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.44) by 54.55 percent. This is a 780 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $5.06 million which met the analyst consensus estimate. This is a 6.08 percent increase over sales of $4.77 million the same period last year.

Earnings Misses

MediWound Q2 Adj $(0.68) Misses $(0.42) Estimate, Sales $5.06M Inline

AST SpaceMobile (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) is set to report its second-quarter 2024 results on Aug 14, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 11.11%, with the bottom line beating the Zacks Consensus Estimate by 2 cents. The company is expected to report a top-line improvement year over year, backed by healthy momentum in both the government and private sector.
<h3>Factors at Play</h3>
During the quarter, AST SpaceMobile inked a definitive commercial agreement with AT&amp;T. Per the deal, AT&amp;T is set to leverage ASTS&#39; Space-based direct-to-mobile technology to deliver seamless and reliable connectivity to consumers and expand coverage into remote, rural and hard-to-reach locations across the continental United States.
Verizon, another major player in the U.S. telecom industry, also signed a deal with the company to deliver seamless connectivity to remote corners of the country utilizing ASTS&#39; satellite network. Its commercial communication technologies are also gaining traction in the government sector for mission-critical applications. These developments will likely have a favorable impact on the company&#39;s earnings.
For the June quarter, the Zacks Consensus Estimate for total revenues is pegged at $2 million. The company didn&#39;t generate any revenues from in the second quarter of fiscal 2023.&nbsp;
The consensus estimate for adjusted earnings per share indicates a loss of 19 cents per share. It incurred a loss of 24 cents per share in the year-ago quarter.
<h3>Earnings Whispers</h3>
Our proven model does not conclusively predict an earnings beat for AST SpaceMobile this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%.
<div class="chart_embed">
<h3>AST SpaceMobile, Inc. Price and EPS Surprise</h3>
<img alt="AST SpaceMobile, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/e8/1723470331.png" style="height:298px; width:610px" title="" />
AST SpaceMobile, Inc. price-eps-surprise | AST SpaceMobile, Inc. Quote
Zacks Rank: AST SpaceMobile currently has a Zacks Rank #3.
</div>
<h3>Stocks to Consider</h3>
Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
MediWound Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdwd#NASDAQ">MDWD</a>) is set to release quarterly numbers on Aug 14. It has an Earnings ESP of +4.76% and a Zacks Rank #2.
On Holding AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) is scheduled to report quarterly numbers on Aug 13. It has an Earnings ESP of +11.51% and sports Zacks Rank of 1.
The Earnings ESP for Dycom Industries (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dy#NYSE">DY</a>) is +4.43%, and it has a Zacks Rank of 3. The company is scheduled to report quarterly numbers on Aug 21.
<a href="https://www.zacks.com/stock/news/2320784/ast-spacemobile-asts-to-post-q2-earnings-what-s-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2320784">To read this article on Zacks.com click here.</a>

Mid Cap

ASTS

ONON

AST SpaceMobile to Post Q2 Earnings: What's in the Cards?

MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the positive results of the NEXT&mdash;an Expanded Access Protocol. NEXT, initiated in 2019, aimed to ensure the continuous availability of NexoBrid&reg;&nbsp;in burn centers until its commercialization. This program successfully maintained physician expertise, provided burn victims with ongoing access to this life-saving treatment, and facilitated the accumulation of real-world safety and clinical data for NexoBrid. 
&nbsp;
Jeremy Goverman, MD, FACS, Associate Professor of Surgery at Harvard Medical School, commented, &quot;The NEXT results reaffirm the significant benefits of NexoBrid in managing severe burns. This enzymatic debridement agent accelerates the debridement process and reduces the need for surgical interventions, ultimately enhancing patient outcomes. The findings from NEXT are consistent with data from the DETECT and CIDS Phase III trials, reinforcing the critical role that NexoBrid should play in standard burn care protocols.&quot;
NEXT, an open-label, single-arm treatment protocol was conducted at 29 burn centers across the U.S. 239 patients, including 215 adults and 24 children, with deep partial and full-thickness thermal burns covering up to&nbsp;30%&nbsp;of the total body surface area (TBSA) were treated with NexoBrid.
Key Results of the NEXT Protocol Include:
<ul>
<li>Efficacy&nbsp;(findings were consistent with Phase III studies results):
<ul>
<li>94.9%&nbsp;of adults and&nbsp;100%&nbsp;of children achieved complete debridement.</li>
<li>Only&nbsp;4.2%&nbsp;of adults required surgical excision for eschar removal after NexoBrid treatment, and none in the pediatric group.</li>
<li>The mean (&plusmn; SD) percent of wound area surgically excised for adults was&nbsp;3.6%&nbsp;(&plusmn;18.33), and&nbsp;0%&nbsp;for children.</li>
<li>The time to complete eschar removal was less than one day for both adults and children.</li>
</ul>
</li>
<li>Healing and Hospitalization:
<ul>
<li>The median time to wound closure was 22 days (95%&nbsp;CI: 22, 23) for adults and 28 days (95%&nbsp;CI: 18, 32) for children.</li>
<li>The median time of hospitalization duration was 10 days (95%&nbsp;CI: 8, 11) for adults and 10 days (95%&nbsp;CI: 5, 14) for children.</li>
</ul>
</li>
<li>Safety:&nbsp;The safety data was consistent with the established safety profile of NexoBrid, and no new safety concerns were identified by the Data Safety and Monitoring Board (DSMB).</li>
<li>Benefit-Risk Ratio:&nbsp;The overall benefit-to-risk ratio of NexoBrid treatment remains favorable.</li>
</ul>

MediWound Announces Results from NEXT Protocol for NexoBrid in Burn Treatment

Press Releases

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound to Report Third Quarter 2024 Financial Results

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025

MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Comments

MediWound

Notizie

Ultime notizie per MediWound (NASDAQ:MDWD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO